Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on Non-Small Cell Lung Cancer (NSCLC) in stages IB-IIIA with uncommon EGFR mutations in patients who have had complete tumor removal through surgery. The study aims to evaluate whether adding zipalertinib to standard treatment with chemotherapy works better than chemotherapy with placebo in preventing cancer from returning after surgery.

The treatment involves taking zipalertinib or placebo tablets by mouth, combined with chemotherapy medications given through an intravenous infusion. The chemotherapy drugs used in this study are cisplatin, carboplatin, and pemetrexed. These medications are commonly used to treat lung cancer after surgery to reduce the risk of cancer coming back.

During the study, participants will be randomly assigned to receive either zipalertinib tablets or matching placebo tablets. Neither the participants nor their doctors will know which treatment they are receiving. The treatment period may last up to 36 months, during which participants will receive regular medical check-ups to monitor their health and evaluate how well the treatment is working.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment phase

    You will receive treatment 4-10 weeks after your lung cancer surgery

    Your treatment will combine chemotherapy given through an intravenous infusion with either zipalertinib tablets or placebo tablets

    The chemotherapy will include either cisplatin or carboplatin, combined with pemetrexed

  2. Step 2

    Daily medication

    You will take either zipalertinib tablets or placebo tablets daily as prescribed

    The tablets should be taken by mouth according to the provided schedule

  3. Step 3

    Monitoring period

    Regular assessments will check your health status and monitor for any changes in your condition

    Brain scans (MRI or CT) will be performed as part of your follow-up care

    Your doctor will monitor your organ function through blood tests

  4. Step 4

    Follow-up requirements

    After completing treatment, you must use effective birth control for at least 1 month after the last dose of zipalertinib/placebo

    If you received chemotherapy, birth control must continue for 6 months after the last dose

    Your health status will continue to be monitored to assess the treatment's effectiveness

  5. Step 5

    Study duration

    The study is expected to run from October 2025 to December 2030

    Your individual participation duration will be determined by your treatment plan

Who can join the trial?

17 criteria

  • Must be 18 years of age or older
  • Must provide written informed consent
  • Must have adequate organ function including:
    • Sufficient blood cell counts
    • Good kidney function
    • Normal blood clotting function
    • Normal liver function
    • Must have non-small cell lung cancer (NSCLC) that has been surgically removed with clear margins (no cancer cells at the edges of removed tissue)
    • Cancer must be classified as Stage IB, IIA, IIB, or IIIA
    • Must have specific genetic changes in the EGFR gene confirmed by laboratory testing
    • Must have had brain imaging (MRI or CT scan) before surgery or before starting the study
    • Must have fully recovered from surgery, with complete wound healing
    • Must start treatment between 4 and 10 weeks after surgery
    • Must be able to perform daily activities with minimal assistance (ECOG Performance Status of 0 or 1)
    • Must have tumor tissue available for laboratory testing
    • For women who can become pregnant:
      • Must have a negative pregnancy test within 7 days before starting treatment
      • Must use effective birth control during the study and for 1 month after last dose
      • For men who can father children:
        • Must use effective birth control during the study and for 6 months after last dose

Who cannot join the trial?

15 criteria

  • Age below 18 years or above 75 years
  • Previous treatment with any EGFR inhibitor (drugs that target specific proteins in cancer cells)
  • Known allergy or sensitivity to study medications
  • Active or untreated brain metastases (cancer that has spread to the brain)
  • Significant heart conditions including:
    • Uncontrolled high blood pressure
    • Recent heart attack (within 6 months)
    • Unstable heart rhythm problems
    • Severe kidney or liver dysfunction
    • Currently participating in another clinical trial
    • Pregnant or breastfeeding women
    • Any other active cancer requiring treatment
    • Major surgery within 4 weeks before starting the study
    • Any serious medical condition that could interfere with study participation
    • Unable to swallow oral medications
    • History of organ transplantation
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Zipalertinib

    is a targeted therapy medication used to treat non-small cell lung cancer (NSCLC). It specifically works by targeting uncommon mutations in the EGFR (epidermal growth factor receptor) gene. This medication is being studied in patients who have had their tumors surgically removed and are receiving chemotherapy to prevent cancer recurrence.

  • Chemotherapy

    refers to standard cancer-fighting drugs that are given after surgery (adjuvant therapy) to kill any remaining cancer cells and reduce the risk of cancer coming back. In this trial, chemotherapy is given to all patients along with either zipalertinib or placebo.

What is already known about the treatment

Zipalertinib – A novel targeted therapy medication designed for oral administration in the treatment of non-small cell lung cancer (NSCLC), specifically targeting uncommon EGFR mutations in patients with stage IB-IIIA disease. This drug works by selectively inhibiting the epidermal growth factor receptor (EGFR) signaling pathway at the molecular level, which helps control cancer cell growth and survival. Currently undergoing Phase 3 clinical trials, zipalertinib is being studied in combination with adjuvant chemotherapy for patients who have undergone complete tumor resection, representing a potential advancement in personalized cancer treatment approaches.

Investigated diseases

Non-small Cell Lung Cancer (NSCLC) - A type of lung cancer that begins in the epithelial cells of the lung tissue. The disease starts when abnormal cells in the lungs begin to grow and multiply uncontrollably, forming tumors. Stage IB-IIIA indicates that the cancer has grown into deeper lung tissues and may have spread to nearby lymph nodes. In cases involving EGFR mutations, the cancer cells have specific changes in the epidermal growth factor receptor gene, which affects how the cells grow and divide. NSCLC typically develops slowly and may not cause symptoms in its early stages.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2025-521775-31-00Protocol codeTAS6417-302Estimated enrolment405 patientsSponsorTaiho Oncology Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.